131 results
Page 4 of 7
6-K
EX-99.1
snfsjva2h24ryr
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-99.3
l2d spdcqh
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-99.1
23zbf9kj 3hmcdf6b
26 Apr 22
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
8:05am
6-K
EX-1.1
a1wq 23o6r09fta9f
11 Feb 22
Current report (foreign)
5:29pm
424B5
8jpu pxxzf
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.3
c2pp60rc7xx6tacm8
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
ew99gx8c vj4odf
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
exsatnpabn2m9q
5 Oct 21
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
4:17pm
6-K
EX-99.1
qbjrlqmfmmqp
17 Sep 21
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to
7:36am
6-K
EX-99.2
45o6k669 bfee08
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
cgnphc4q0dxnp bblvk
30 Aug 21
Current report (foreign)
7:50am
6-K
5pka6d
16 Aug 21
Current report (foreign)
7:00am
6-K
EX-99.1
6vxqt5hrervfgtti0zx
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
cm1cpetdk23zu8
4 Jun 21
Current report (foreign)
8:05am
6-K
r1kb4
11 May 21
Current report (foreign)
7:00am
424B8
4ago799upd8
19 Apr 21
Prospectus unintentially filed late
5:06pm
6-K
EX-1.1
ij88664 nrn
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
6-K
EX-99.1
ox72 5vpd
12 Apr 21
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
9:10am
424B5
86tmz 1hh3
12 Apr 21
Prospectus supplement for primary offering
9:07am